Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 3 (March)

1. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.
   Hum Mol Genet, 15(6): 1015-23. [Abstract] [Full-text]
2. Chronic Eosinophilic Leukemia with the FIP1L1-PDGFRalpha Fusion Gene in a Patient with a History of Combination Chemotherapy.
   Int J Hematol, 83(2): 152-5. [Abstract] [Full-text]
3. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
   Blood, 107(6): 2501-6. [Abstract] [Full-text]
4. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
   Cancer Lett, 233(2): 328-37. [Abstract] [Full-text]
5. Kinase inhibitors and airway inflammation.
   Eur J Pharmacol, 533(1): 118-32. [Abstract] [Full-text]
6. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
   Bone Marrow Transplant, 37(6): 575-82. [Abstract] [Full-text]
7. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
   Cancer, 106(6): 1306-15. [Abstract] [Full-text]
8. Making a Notch in the lymphocyte kit.
   Eur J Immunol, 36(3): 508-11. [Abstract] [Full-text]
9. Critical role for c-kit (CD117) in T cell lineage commitment and early thymocyte development in vitro.
   Eur J Immunol, 36(3): 526-32. [Abstract] [Full-text]
10. Functional SNPs of the breast cancer resistance protein - therapeutic effects and inhibitor development.
    Cancer Lett, 234(1): 73-80. [Abstract] [Full-text]
11. Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells.
    Biochem Biophys Res Commun, 342(4): 1405-12. [Abstract] [Full-text]
12. Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines.
    Pharmacology, 77(1): 11-16. [Abstract] [Full-text]
13. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.
    Proc Natl Acad Sci U S A, 103(10): 3563-8. [Abstract] [Full-text]
14. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers.
    J Mass Spectrom, 41(3): 390-404. [Abstract] [Full-text]
15. An audit of surgical management of gastrointestinal stromal tumours (GIST).
    Eur J Surg Oncol, 32(3): 310-4. [Abstract] [Full-text]
16. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib.
    Radiographics, 26(2): 481-95. [Abstract] [Full-text]
17. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Clin Cancer Res, 12(6): 1743-9. [Abstract] [Full-text]
18. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
    Leukemia, 20(4): 664-70. [Abstract] [Full-text]
19. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
    Leukemia, 20(4): 650-7. [Abstract] [Full-text]
20. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
    Leukemia, 20(4): 658-63. [Abstract] [Full-text]
21. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
    Leukemia, 20(4): 671-9. [Abstract] [Full-text]
22. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.
    Leukemia, 20(4): 680-8. [Abstract] [Full-text]
23. Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model.
    Am J Respir Crit Care Med, 173(7): 769-776. [Abstract] [Full-text]
24. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
    BMC Cancer, 6(1): 79. [Abstract] [Full-text]
25. Multicellular Tumour Spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring.
    Cancer Cell Int, 6(1): 6. [Abstract] [Full-text]
26. Advances in the treatment for haematological malignancies.
    Expert Opin Pharmacother, 7(6): 721-32. [Abstract] [Full-text]
27. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Am J Hematol, 81(4): 242-55. [Abstract] [Full-text]
28. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
    Leuk Res, 30(6): 701-5. [Abstract] [Full-text]
29. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
    Cancer, 106(7): 1617-23. [Abstract] [Full-text]
30. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
    J Am Coll Surg, 202(4): 623-9. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.